---
title: "Penumbra | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 374.76 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285432719.md"
datetime: "2026-05-06T20:26:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285432719.md)
  - [en](https://longbridge.com/en/news/285432719.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285432719.md)
---

# Penumbra | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 374.76 M

Revenue: As of FY2026 Q1, the actual value is USD 374.76 M, beating the estimate of USD 372.04 M.

EPS: As of FY2026 Q1, the actual value is USD 0.82, missing the estimate of USD 1.0768.

#### Revenue Performance

Penumbra, Inc. reported total revenue of $374.8 million in the first quarter of 2026, marking a 15.6% increase compared to the first quarter of 2025 .

##### Revenue by Product Category

Global thrombectomy revenue reached $253.9 million in Q1 2026, an increase of 12.1% from Q1 2025 . Global embolization and access revenue was $120.8 million in Q1 2026, showing a 23.8% increase compared to Q1 2025 .

##### Revenue by Geographic Region

United States revenue was $296.387 million in Q1 2026, up 15.4% . International revenue was $78.371 million in Q1 2026, representing a 16.5% increase .

#### Operational Metrics

The gross profit margin for the first quarter of 2026 was 67.6%, an increase of 1.0% compared to the first quarter of 2025 . Total operating expenses amounted to $215.2 million in Q1 2026, which included $22.4 million for Research and Development (R&D) and $192.8 million for Selling, General, and Administrative (SG&A) expenses . Notably, SG&A expenses included $9.4 million in acquisition-related expenses tied to the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation . Income from operations was $38.2 million in the first quarter of 2026 . Net income for the first quarter of 2026 was $32.6 million .

#### Financial Position (as of March 31, 2026)

Cash and cash equivalents totaled $241.289 million . Total assets were $1,898.438 million . Total liabilities amounted to $424.626 million . Total stockholders’ equity was $1,473.812 million .

#### Outlook / Guidance

Penumbra, Inc. will not be providing financial guidance for the full year 2026 due to its pending acquisition by Boston Scientific Corporation . Consequently, the company will also not host a conference call to discuss its financial results for the three months ended March 31, 2026 .

### Related Stocks

- [PEN.US](https://longbridge.com/en/quote/PEN.US.md)

## Related News & Research

- [3,550 Shares in Penumbra, Inc. $PEN Bought by Radnor Capital Management LLC](https://longbridge.com/en/news/286893569.md)
- [New York Life Investment Management LLC Takes $999,000 Position in Penumbra, Inc. $PEN](https://longbridge.com/en/news/287032637.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Royce Small-Cap Trust (NYSE: RVT) as of Apr 30, 2026 | RVT Stock News](https://longbridge.com/en/news/287103750.md)